Skip to content

Clinical study of pediatric spleen and lung clearing prescription in the treatment of pulmonary and spleen dampness and heat syndrome in children with cough and asthma

Clinical study of pediatric spleen and lung clearing prescription in the treatment of pulmonary and spleen dampness and heat syndrome in children with cough and asthma

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2024000701
Enrollment
Unknown
Registered
2024-11-13
Start date
2024-07-01
Completion date
Unknown
Last updated
2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute bronchitis

Interventions

Control group:Pediatric patients with cough syndrome with lung-spleen damp-heat syndrome are treated with symptomatic supportive treatment such as antiviral, antibacterial, antipyretic, and rehydratio
Experimental group:In addition to the symptomatic supportive treatment of antiviral antibacterial antipyretic and fluid rehydration of conventional Western medicine pediatric cough patients with lung

Sponsors

Sun Simiao Hospital Beijing University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to 14 Years

Inclusion criteria

Inclusion criteria: 1. Children aged 1 = = 14 years old; 2. Patients with acute bronchitis who meet the pulmonary and spleen damp-heat syndrome. (1) Diagnostic criteria of Western medicine: refer to the diagnosis of acute bronchitis in the 9th edition of "Zhufutang Practical Pediatrics". (2) TCM diagnosis: According to the "Guidelines for Common Diagnosis and Treatment of Pediatric Diseases in TCM" and "TCM Clinical Diagnosis and Treatment Part 2 · Syndromes" as the standard the diagnosis of TCM diseases refers to "cough". 3. The legal guardian signed the informed consent form and voluntarily participated in this study.

Exclusion criteria

Exclusion criteria: (1) Combined with congenital heart disease bronchopulmonary dysplasia respiratory malformations lung tumors tuberculosis brain dysplasia neurological and muscular diseases chronic liver and kidney diseases hematopoietic diseases etc.; (2) Patients with primary autoimmune deficiency or acute infectious diseases; (3) Children with a history of severe allergies or asthma in the past or allergies to the drugs used in this study; (4) Children with genetic diseases such as Down syndrome trisomy 18 phenylketonuria and juvenile diabetes; (5) After active treatment the condition does not improve and the course of the disease is more than 1 week; (6) Patients who have participated in or are participating in other drug clinical trials within the last 3 months.

Design outcomes

Primary

MeasureTime frame
Laboratory tests during hospitalization;Patient symptom and sign change score;

Secondary

MeasureTime frame
Outcome of hospital discharge;

Countries

China

Contacts

Public ContactXiaohong Gu

Beijing University of Chinese Medicine

guxiaohong1962@163.com01064286998

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026